Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumAndréa Lessa Benedet, Alyssa Stevensson, Natàlia Vilor‐Tejedor et al.|JAMA Neurology|2021Cited by 627
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detectedMarc Suárez‐Calvet, Natàlia Vilor‐Tejedor, Thomas K. Karikari et al.|EMBO Molecular Medicine|2020Cited by 411
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s diseaseMarta Milà‐Alomà, Kaj Blennow, Nicholas J. Ashton et al.|Nature Medicine|2022Cited by 349
Quantification of amyloid PET for future clinical use: a state-of-the-art reviewHugh Pemberton, Gill Farrar, Lyduine E. Collij et al.|European Journal of Nuclear Medicine and Molecular Imaging|2022Cited by 211
Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuumNatàlia Vilor‐Tejedor, Marc Vilanova, Iacopo Ciampa et al.|Alzheimer s Research & Therapy|2021Cited by 68